Evidence map›Paper›PMID 38618294›Full record

ArticleJournal of pain research2024

Current Status of Cognition and Clinical Practice of Refractory Cancer Pain in Shanghai: A Questionnaire Survey.

Jing Zhang, Ke Ma, Jun Yan, Pingsheng Pan, Jiangshan Yin, Fuqing Lin, Hui Chen, Weiwei Zhao, Menglei Chen, Zhe Zhang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management.Frontiers in pain research (Lausanne, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Jing ZhangDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID 0000-0001-6057-1460
Ke MaDepartment of Pain Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Jun YanDepartment of Oncology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, People's Republic of China.
Pingsheng PanDepartment of Oncology, Fangta Hospital of Traditional Chinese Medicine in Songjiang District, Shanghai, People's Republic of China.
Jiangshan YinDepartment of Oncology, Fudan University Shanghai Cancer Center, Minhang Branch, Shanghai, People's Republic of China.
Fuqing LinDepartment of Anaesthesiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
Hui ChenDepartment of Anesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, People's Republic of China.
Weiwei ZhaoDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Menglei ChenDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Zhe ZhangDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Minghui LiuDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Xiaoli GuDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Xinghe LiaoDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID 0000-0001-6158-4693
Chenyue ZhangDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Wenwu ChengDepartment of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Shanghai Medical College of Fudan University · CNTongji University · CNFudan University Shanghai Cancer Center · CNJiading District Central Hospital · CNShanghai Jiao Tong University · CNSongjiang District Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to assess the current status of clinical practice of refractory cancer pain (RCP) among a sample of physicians specializing in cancer pain management in Shanghai. Methods: From 2019 to 2021, a questionnaire survey was conducted among physicians engaged in diagnosis and treatment of cancer pain through the questionnaire WJX network platform in Shanghai, China. Results: A total of 238 responses participated in the survey. This survey reports physicians' understanding and incidence rate of breakthrough cancer pain (BTCP). The choice of analgesics and satisfaction of analgesic effect were investigated. We also investigated doctors' knowledge of the diagnostic criteria for RCP and their tendency to choose analgesics. Oral immediate-release morphine and intravenous or subcutaneous morphine injection have been the common treatment approach for transient cancer pain exacerbations. The main barriers to pain management are lack of standardized treatment methods for RCP, lack of knowledge related to RCP, and single drug dosage form. Doctors believe the most necessary measures to improve the current situation of poor cancer pain control include improving medical staff's understanding and treatment techniques for RCP, updating treatment techniques and methods, and improving the configuration of drug types in medical institutions. Clinicians expect to improve understanding and treatment techniques through systematic training. Conclusion: Despite multiple available analgesic measures, the treatment of RCP remains challenging. Improving the understanding of medical staff towards RCP, improving treatment techniques, and increasing the accessibility of multiple drug types are important ways to improve the satisfaction of cancer pain management in the future.

Indexed as

breakthrough cancer painopioid drugspain managementrefractory cancer pain

Identifiers

PMID38618294
PMCPMC11015849
OpenAlexW4394613491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.